As dermatologists gain experience with newer atopic dermatitis medications, they’re getting glimpses of data from a pipeline full of potential therapies, according to Lawrence Eichenfield, M.D.
It’s a revolution in atopic dermatitis therapy that promises to treat patients of all ages and suffering from every aspect of the disease—from rashes, itch and sleep disturbances, to secondary effects, like anxiety and depression, he says.
Researchers are studying approved atopic dermatitis drugs in younger patients, according to Dr. Eichenfield, chief of pediatric and adolescent dermatology at Rady Children’s Hospital San Diego, and professor of dermatology and pediatrics at the University of California San Diego School of Medicine. Pfizer recently announced that it completed a study of topical crisaborole (Eucrisa) in atopic dermatitis patients younger than two years.
“It appeared safe, but we haven’t yet heard the details of the data and the status of expanded specific indication for use of crisaborole under age two,” says Dr. Eichenfield, who also is on the National Eczema Association’s Scientific Advisory Committee.
The FDA has approved dupilumab (Dupixent, Sanofi and Regeneron Pharmaceuticals), an interleukin (IL)-4 and IL-13 blocker, in adults and patients ages 12 to 17 years with moderate-to-severe atopic dermatitis.
Dr. Eichenfield has consulting and/or research ties to Allergan, Almirall, Dermira, DS Laboratories, Galderma, Glenmark, Incyte, LEO Pharma, Lilly, Novan, Otsuka Pharmaceutical Co., Pfizer, Sanofi-Regeneron, Ortho Dermatologics/Valeant.